Acute heart failure (HF) is a clinical syndrome with multiple aetiologies, among which acute coronary syndrome constitutes one of the most frequent precipitating factors, especially in developed countries [1]. The treatment of AHF is largely based on diuretics being adjusted according to the volemic state, hemodynamic stability and symptoms/signs [1]. Based on their proven benefit in the reduction of HF re-admissions and cardiovascular deaths, regardless of ejection fraction (EF), Sodium-glucose transporter Inhibitors 2 (SGLT2i) are currently recommended only in patients with chronic heart failure (HF) in an outpatient setting [2].
